WEST LAFAYETTE, Ind., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Monday, Feb. 25, at 4:30 p.m. EST to discuss its fourth quarter and full year 2012 financial results and provide an operational update.
Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investor Relations section of the Company's website at www.endocyte.com or by dialing (877) 845-0711 (U.S./Canada) or (760) 298-5081 (International).
A replay of the call will be available beginning at 7:30 p.m. EST on Feb. 25, until midnight EST on March 4, 2013. To access the replay, please dial (855) 859-2056 (U.S./Canada) or (404) 537-3406 (International) and reference the conference 93752119. Additionally, the webcast will be recorded and available on the Company's website for two weeks following the call.Investor and Analyst Day The Company also announced that it will hold an Investor and Analyst Day, during which Endocyte's senior management team will discuss the Company's strategic objectives, its programs for vintafolide and etarfolatide, its commercial strategies and its advancing pipeline of candidates targeting oncology and inflammation. The event will be held on March 22, 2013, from 9:30 a.m. to 1 p.m. EDT at the Setai Fifth Avenue in New York City. About Endocyte Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.